Our objective was to quantify the presence of markers of amyloid pathology (total Aβ, Aβ-40, Aβ-42, and soluble Aβ) and a marker of hyperphosphorylated tau pathology in post-stroke subjects with and without dementia compared to aging controls, Alzheimer's disease (AD) and mixed AD and vascular dementia (AD-VaD). This evidence concerns the gene MAPT and amyloidosis.